Foghorn Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
FHTX$2.04+9.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $80,336 | $52,214 |
| Marketable securities | 153,721 | 293,584 |
| Prepaid expenses and other current assets | 6,124 | 5,601 |
| Total current assets | 240,181 | 351,399 |
| Property and equipment, net | 12,956 | 15,311 |
| Restricted cash | 1,708 | 1,708 |
| Other assets | 1,115 | 2,379 |
| Operating lease right-of-use assets | 29,956 | 34,086 |
| Total assets | $285,916 | $404,883 |
| Liabilities and Stockholders’ Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable | $6,260 | $5,414 |
| Accrued expenses and other current liabilities | 9,108 | 11,001 |
| Operating lease liabilities | 8,518 | 5,970 |
| Deferred revenue | 34,550 | 32,820 |
| Total current liabilities | 58,436 | 55,205 |
| Operating lease liabilities, net of current portion | 36,555 | 45,537 |
| Deferred revenue, net of current portion | 268,115 | 304,000 |
| Other liabilities | — | 29 |
| Total liabilities | 363,106 | 404,771 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity (deficit): | ||
| Preferred stock, $0.0001 par value; 25,000,000 shares authorized as of December 31, 2023 and 2022; no shares issued and outstanding as of December 31, 2023 and 2022 | — | — |
| Common stock, $0.0001 par value; 175,000,000 shares authorized at December 31, 2023 and 2022; 42,282,040 shares issued and outstanding at December 31, 2023 and 41,803,436 shares issued and outstanding at December 31, 2022 | 4 | 4 |
| Additional paid-in capital | 395,196 | 377,232 |
| Accumulated other comprehensive loss | (826) | (3,986) |
| Accumulated deficit | (471,564) | (373,138) |
| Total stockholders’ equity (deficit) | (77,190) | 112 |
| Total liabilities and stockholders’ equity (deficit) | $285,916 | $404,883 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.